<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690115</url>
  </required_header>
  <id_info>
    <org_study_id>P1701_ PONALLO</org_study_id>
    <nct_id>NCT03690115</nct_id>
  </id_info>
  <brief_title>Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients</brief_title>
  <acronym>PONALLO</acronym>
  <official_title>Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent advances in acute myeloid leukemia (AML) have been characterized by a better&#xD;
      understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem&#xD;
      duplication (FLT3-ITD) have been recognized as conferring a poor prognosis. The FLT3-ITD&#xD;
      molecular mutation is observed in about one-quarter of patients diagnosed with AML. Patients&#xD;
      presenting with this abnormality are referred for early allogeneic stem-cell transplantation&#xD;
      (allo-SCT). However, some data suggest that FLT3-ITD remains associated with a poor prognosis&#xD;
      even after allo-SCT because of higher risk of relapse and strategies for preventing relapse&#xD;
      in the post-transplant setting are required (Hu et al, Expert Rev Hematol, 2014). For&#xD;
      example, in a large cohort of patients (Brunet et al, JCO, 2012), the incidence of relapse&#xD;
      for FLT3-ITD AML patients after allo-SCT was 30% at 2-years, significantly higher compared to&#xD;
      FLT3-ITD negative patients (p=0.006).&#xD;
&#xD;
      Ponatinib (Iclusig®) is an orally available, tyrosine kinase inhibitor with a unique binding&#xD;
      mechanism allowing inhibition of BCR-ABL kinases, including those with the T315I point&#xD;
      mutation. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases&#xD;
      implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT,&#xD;
      fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α&#xD;
      (PDGFRα). In vitro activity of ponatinib in AML has been already demonstrated (Gozgit et al,&#xD;
      Mol Cancer Ther, 2011; Smith et al, Blood 2013). If some trials are on-going to test&#xD;
      ponatinib alone or in combination with chemotherapy in FLT3-ITD AML (Clinical.trials.gov), no&#xD;
      study is dedicated to the use of ponatinib in the post-transplant setting in order to prevent&#xD;
      relapse in these patients.&#xD;
&#xD;
      The main goal of this study will be to determine the maximal tolerated dose (MDT) of&#xD;
      ponatinib after allo-SCT in FLT3-ITD AML patients, then to investigate the efficacy of&#xD;
      ponatinib in a larger cohort of patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse incidence at 2 years from transplant</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>time interval from the graft (day 0) until the date of last follow-up or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>2 years</time_frame>
    <description>time interval from the date of the graft (day 0) until the date of last follow-up, death or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>day 100</time_frame>
    <description>incidence of mortality due to all causes except relapse after transplant, considering that cause of death for patients having relapsed but dying from another cause is relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>NIH score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Ponatinib on Immune reconstitution PB lymphocyte cells</measure>
    <time_frame>1 years</time_frame>
    <description>an immunophenotype of PB lymphocytes will be performed by flow cytometry at +3, +6, +9 and +12 months post-transplant to study the reconstitutions of CD3, CD4 and CD8 T cells, B and NK cells. The results will be expressed as absolute counts (Giga/L). We want to establish the potential influence of ponatinib on the reconstitution of these cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflence of Ponatinib on Chimerism of Donor peripheral blood and CD3 T cells</measure>
    <time_frame>1 years</time_frame>
    <description>Donor peripheral blood and CD3 T cells chimerism will be studied using molecular markers and RT-PCR at day +30, +60, +90, and +6, +12 months post-transplant. We want to establish the potential influence of ponatinib on the chimerism post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 30 MG</intervention_name>
    <description>Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Engraftment&#xD;
&#xD;
          -  Controlled GVHD&#xD;
&#xD;
          -  Positive FLT-3 ITD AML in cytologic complete remission&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2&#xD;
&#xD;
          -  Have adequate renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) for&#xD;
             institution&#xD;
&#xD;
          -  Have adequate hepatic function: Total serum bilirubin ≤ 1.5 × ULN, unless due to&#xD;
             Gilbert's syndrome; Alanine aminotransferase (ALT) ≤ 2.5 × ULN, or ≤ 5 × ULN if&#xD;
             leukemic infiltration of the liver is present ; Aspartate aminotransferase (AST) ≤ 2.5&#xD;
             × ULN, or ≤ 5 × ULN if leukemic infiltration of the liver is present&#xD;
&#xD;
          -  Have normal pancreatic status: Serum lipase and amylase ≤ 1.5 × ULN&#xD;
&#xD;
          -  Have normal QTcF interval on screening electrocardiogram (ECG) evaluation,defined as&#xD;
             QTcF of ≤ 450 ms in males or ≤ 470 ms in females.&#xD;
&#xD;
          -  Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l&#xD;
&#xD;
          -  Have a negative pregnancy test documented prior to enrollment (for females of&#xD;
             childbearing potential).&#xD;
&#xD;
          -  Agree to use an effective form of contraception with sexual partners throughout study&#xD;
             participation (for female and male patients who are fertile).&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits and study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive, active Hepatitis B or C&#xD;
&#xD;
          -  Childbearing or childbreast feeding women&#xD;
&#xD;
          -  Women or men without effective contraceptive barrier if needed&#xD;
&#xD;
          -  Previous myocardial infarction, or cerebral vascular accident, pancreatitis&#xD;
&#xD;
          -  Respiratory insufficiency defined as DLCO &lt;40% of the corrected value&#xD;
&#xD;
          -  Creatinine clearance ≤ 50ml/min&#xD;
&#xD;
          -  Contra-indication to ponatinib&#xD;
&#xD;
          -  Previous or concurrent second malignancy except for adequately treated basal cell&#xD;
             carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively&#xD;
             treated solid cancer, with no evidence of disease for at least 2 years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Patients at high or very high risk of cardiovascular disease with any of the following&#xD;
&#xD;
               1. Established cardiovascular disease Cardiac disease:&#xD;
&#xD;
                    -  Congestive heart failure greater than class II NYHA or&#xD;
&#xD;
                    -  Left ventricular ejection fraction (LVEF) &lt; 50% or&#xD;
&#xD;
                    -  Unstable angina (anginal symptoms at rest) or&#xD;
&#xD;
                    -  New onset angina (began within the last 3 months) or&#xD;
&#xD;
                    -  Myocardial infarction, coronary/peripheral artery disease, congestive heart&#xD;
                       failure, cerebrovascular accident including transient ischemic attack within&#xD;
                       the past 12 months or&#xD;
&#xD;
                    -  History of thrombolic or embolic events Arrhythmias&#xD;
&#xD;
                    -  Any history of clinically significant cardiac arrhythmias requiring&#xD;
                       anti-arrhythmic therapy.&#xD;
&#xD;
               2. Diabetes Mellitus,&#xD;
&#xD;
               3. Arterial Hypertension,&#xD;
&#xD;
                    -  Uncontrolled hypertension defined as systolic blood pressure greater than&#xD;
                       140 mmHg or diastolic pressure greater than 90 mmHg, despite optimal medical&#xD;
                       management and optimal measurement&#xD;
                       (http://www.has-sante.fr/portail/display.jsp?id=c_272459)&#xD;
&#xD;
                    -  Any history of hypertension with&#xD;
&#xD;
                    -  Hypertensive encephalopathy&#xD;
&#xD;
                    -  Posterior leucoencephalopathy&#xD;
&#xD;
                    -  Aortic or artery dissection&#xD;
&#xD;
               4. Familial dysplipidemia.&#xD;
&#xD;
               5. Taking medications that are known to be associated with Torsades de Pointes (see&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure MORISSET</last_name>
    <phone>+33139239785</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHu Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillerm</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantepie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guieze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bulabois</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yakoub Agha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Turlure</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chevallier</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mothy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Peffault de la tour</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHu Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Labussière</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maillard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRLC Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huynh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rubio</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nantes University Hospital</investigator_affiliation>
    <investigator_full_name>Patrice Chevallier</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

